MMRF Patient Webinar:
Maintenance Therapy for Multiple Myeloma Patients
EVENT DETAILS
In multiple myeloma management, the goals of maintenance therapy are to maintain treatment response for as long as possible and to extend survival. A growing body of evidence supports the role of maintenance therapy after the completion of induction therapy or after transplantation. Currently, Revlimid is the only drug approved as maintenance therapy for myeloma patients following a stem cell transplant. However, because some patients are unable to tolerate Revlimid for an extended time, many other drugs are also being investigated as maintenance therapy.